Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients aged 50–75 with advanced myelodysplastic syndrome who were matched with a stem cell transplant donor and those who did not receive transplant. After three years, individuals with donors achieved around 50% survival, while those with no donor had approximately 30% survival. Dr. Cutler hopes to see more patients referred early on for transplantation to enhance chances of receiving stem cell transplants.
- Patients with a history of a hematologic malignancy who survive #COVID-19 infection have similar immune responses a… https://t.co/AHnuRwuR84
- Clarity on Disparity: Black patients with acute myeloid #leukemia (#AML) under the age of 60 have a 27% higher risk… https://t.co/3eU0hdWeCI
- During #ASH20, the @AML_Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, about th… https://t.co/SsP7pVq4Zu
- Discontinuation of eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome, particularl… https://t.co/IHfAzMciYP
- If you have been affected by #AML, you're not alone. Speak to your doctor, a specialist nurse, or your local suppor… https://t.co/VdZTU6wfdZ
- Presented by @CLachowiez at #ASH20: Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating fa… https://t.co/toeBzhm8GQ
- In his latest Editor’s Corner, Ari Giagounidis, MD, surveyed international hematologists about the rules regarding… https://t.co/Tz3KVsZd70
- In case you missed it ? Take a look at this animated video by Christine Spencer, Diwakar Davar and the @aml_hub whi… https://t.co/z9WY4303Qg
- Brain Drain: Among 509 patients with COVID-19 treated within a hospital network in Chicago, 82.3% had neurologic sy… https://t.co/IDl4swCL4o
- Combined p53 activation, through MDM2 inhibition, and BRD4-directed BET inhibition demonstrates encouraging preclin… https://t.co/Gmu0RdouH9
- In November 2020, eprenetapopt (APR-246) received @US_FDA Fast Track designation for the treatment of AML. Read mor… https://t.co/rb6a6uGnEm
- Results from the phase Ib/II study evaluating the safety, recommended phase II dose, and efficacy of eprenetapopt +… https://t.co/cI0xBbUQqP
- The co-chairs of this year’s #ASH20 Special Symposium on Quality, Sarah H. O’Brien, MD, and @NTConnell invited trai… https://t.co/fteIt4A2yW
- Achievement of measurable residual disease negativity is associated with significant improvements in survival in pa… https://t.co/brl9CVlqmg
- ?In case you missed it ? Residual circulating tumor DNA as a prognostic biomarker in patients with AML/MDS ??… https://t.co/pPsT4SLpTO
- In an analysis of data from the first 250 patients enrolled in the @ASHCollab COVID-19 Registry for Hematology, res… https://t.co/L6TEcSPngt
- RT @JNCI_Now: Survivors of childhood acute myeloid leukemia are at increased risk of long-term neurocognitive and psychosocial impairment c…
- The just-published mid-January Annual Meeting Edition features highlights from #ASH20, a look at doctor-patient gif… https://t.co/R12xbz7wt3
- NEWS | @US_FDA clears IND application for the engineered hematopoietic stem cell therapy, VOR33, which is being inv… https://t.co/uOP30JXmOs
- In case you missed it ? The @AML_Hub provided a summary of the explorative study evaluating the impact of NPM1mut M… https://t.co/ze9o0LqHRm
- #leusm https://t.co/4K792rG6u4
- In case you missed it ? The spectrum of clonal hematopoiesis: a summary of @DrKTakahashi, @MDAndersonNews’s Meet th… https://t.co/iYGOujUfLB
- Latest data from venetoclax plus HMAs for specific AML subpopulations. Read more here: https://t.co/U2l3FO0vJB… https://t.co/vsWSCABtwM
- RT @Anand_88_Patel: In Blood Cancer Journal Dr. Daver et al discuss the rapidly growing (and increasingly complex) landscape of therapies i…
- Progress for All: The gap in health outcomes among racial and ethnic groups shrunk from 1990 to 2016, according to… https://t.co/qJFmWvWGV3
- Written in @BloodJournal: A new AI-based technique was able to establish correlations between genetic and morpholog… https://t.co/q3pCfY2UVc
- ? It's not too late to sign-up for the AML Hub newsletter! Sign up today to get the latest news and expert intervie… https://t.co/650sVU4dma
- Why is self-advocacy so important for someone diagnosed with #AML? @KNOW_AML ambassador Stacey Koleszar from… https://t.co/ihuPIhwTEQ
- A new study published in Science Translational Medicine suggests a simple agent, sodium bicarbonate, could boost T-… https://t.co/T5gYPmrJG2
- “I tell [the junior faculty I mentor], ‘You’re doing good, quality science, so the grants will come. Don’t let the… https://t.co/Uc8rJrSeqo
- The Clot Thickens: Researchers reviewing data from patients enrolled in Danish medical registries found that patien… https://t.co/C5t4K1xShT
- At a list price of $270,000, the cost of anti-von Willebrand factor immunoglobulin fragment caplacizumab outweighs… https://t.co/hrbd33jPfF
- Congratulations to our Koichi Takahashi, M.D., Ph.D., @DrKTakahashi, of @MDAndersonNews #Leukemia, for being select… https://t.co/yxuMvaSzrQ
- Symptoms of relapsed AML may be similar to your first AML diagnosis. Symptoms may include tiredness, breathlessness… https://t.co/Bvg508WiOZ
- During #ASH20, we spoke to Jeffrey Lancet from @MoffittNews. We asked, Why is genetic testing key following an acut… https://t.co/TK8613aR4v
- Would you like to learn more about measurable residual disease (MRD) and when it should be tested? Watch our video… https://t.co/KOM7XcEwBD
- During #ASH20, we spoke to @KNOW_AML ambassador Agnieszka Wierzbowska from the University of Lodz. We asked, What i… https://t.co/BtQcuOohh0
- RT @Coping_Cancer: Happy 60th Birthday to acute myeloid leukemia survivor, @EvanHandler! Read his story from Coping here: https://t.co/HPg…
- RT @LLSusa: Compassion, care and patience for yourself is key, and we are always here for you. ?? Learn more about our support resources f…
- RT @Ankus_ingh: Need help & support for Ryan's Bone Marrow transplant. Ryan is diagnosed with leukemia when he was 4 months old. He is figh…
- Proud to welcome the Philippines Acute #Leukemia & Lymphoma Network to the #KnowAML global network! This associatio… https://t.co/skLOE3nUky
- Relapsed AML can happen any time after treatment. It can occur several months to years after initial treatment. For… https://t.co/9bA6dlU3RQ
- RT @AcuteLeuk: .@LeukaemiaCareUK is hosting a webinar for those affected by acute #leukaemia looking at survivorship on and long-term effec…
- During #ASH20, @KNOW_AML was pleased to speak to Ann-Kathrin Eisfeld @OSUCCC_James, about the impact of race on tre… https://t.co/NjU9P30FaL
- RT @BTMPublicPolicy: Listen to @MDAndersonNews's @CLachowiez speak on relapsed AML treatment strategies, via @KNOW_AML. https://t.co/JivRnz…
- During #ASH20, we spoke to @CLachowiez from @MDAndersonNews about treatment strategies used in relapsed acute myelo… https://t.co/4LjSgZMSEn
- RT @MDAndersonNews: Our cancer patients depend on blood and platelet donations, and right now our need for type O blood donations is especi…
- RT @doctorpemm: Wishing each of you a happy, healthy week filled w/innovation, prosperity & discovery on behalf of our patients with cancer…
- RT @MissionBio: Join us on Nov 9 to hear from two experts in the field of hematology, Dr. Michael Andreeff @MDAndersonNews and Dr. Peter Va…
- RT @gotoPER: Join our #ASH20 FSS Individualizing MF and PV Treatment program with Program Chair Srdan Verstovsek, MD, to keep up to date wi…
- RT @HelixBioPharma: Congrats! @MDAndersonNews Keep up the good work! Thanks to CAR T cell therapy, patients with lymphoma and leukemia have…
- RT @practiceupdate: Leukemic Evolution of Polycythemia Vera and Essential Thrombocythemia. Commentary by Srdan Verstovsek MD @MDAndersonNe…
- RT @VJHemOnc: Did you miss out on the #AML Sessions - venetoclax-based regimens? You can still watch @Daver_Leukemia, Courtney DiNardo, Ma…
- RT @VJHemOnc: ?Don't forget to check out our #AML Sessions w/ @Daver_Leukemia, Courtney DiNardo, Marina Konopleva & Andrew Wei! Now availa…
- RT @power4patients: Which #AML mutations can affect prognosis and treatment? @Daver_Leukemia of @LeukemiaMDA explains. #leusm #FLT3 #IDH1…
- RT @MDAndersonNews: “With immunotherapy, we are trying to harness or reinvigorate the immune system so that it recognizes and attacks the c…
- RT @achlcme: YOUR path, YOUR rules! This enhanced digital algorithm combines stepwise practical guidance with evidence-based education on t…
- RT @yazan_14: Honored to be presenting my first ASH oral presentation!!!. special thanks to @jaltmanmd & @bpromd for their mentorship. @McG…
- RT @ASCO_pubs: Mutant IDH1 inhibitor ivosidenib plus azacitadine was well tolerated in patients with IDH1-mutated newly-diagnosed acute mye…
- RT @doctorpemm: ???Our group’s new paper led by Dr Montalban-Bravo & @garciamanero ?? Clinical Outcomes and Influence of Mutation Clonal Do…
